USPTO serial 98288514
UBC
Reviewed by CopyMark Law Group
Status 688Notice of Allowance
- Filing date
- Status date
- Registration date
- —
- Examiner
- ORDOGNE, ROBERT J
- Law office
- INTENT TO USE SECTION
What this means
The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.
Need help with UBC?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $349*
Plus Government fees of $150
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Blue Bell, PA, US
Blue Bell, PA, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Lisa Casey Spaniel
Lisa Casey Spaniel BLANK ROME LLPONE LOGAN SQUARE8TH FLOORPHILADELPHIA, PA 19103Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 009 | downloadable computer software, computer software platforms, and mobile applications featuring digital assets and artificial intelligence for database management, analytics, modeling, monitoring, storage, validation, compliance, reimbursement management, scheduling, progress monitoring, benefits verification, reimbursements and case management in the field of Clinical Research, Safety Services, Risk Evaluation and Mitigation, Patient Support Services, Evidence Development and Data Analysis | ACTIVE | — |
| 016 | printed materials, namely, brochures, manuals and handbooks featuring topics relating to health, medical and pharmaceutical education, training and testing in connection with patient assistance programs for the pharmaceutical and healthcare industries | ACTIVE | — |
| 035 | medical cost management and administering medication reimbursement programs for others to improve health, affordability and patient experience | ACTIVE | — |
| 036 | Consulting services in the payment management of health care, namely, co-pay cards, therapeutic access, reimbursement, analysis of manufacturer program designs and medication discount benefits | ACTIVE | — |
| 038 | webcasting services featuring topics in the field of health, medical care and pharmaceutical industries | ACTIVE | — |
| 041 | educational, training and educational testing services, namely, conducting seminars, conferences and presentations featuring topics in the field of health, medical care and pharmaceutical industries; training and educational services, namely, conducting programs in the fields of health, medical care and pharmaceutical industries; training and educational services, namely, providing non-downloadable webcasts in the fields of health, medical care and pharmaceutical industries | ACTIVE | — |
| 042 | medical and scientific research, namely, conducting clinical trials for others; basic and clinical research in the field of heath care and medicine; providing on-line non-downloadable software, computer software platforms, and applications featuring artificial intelligence and digital assets used to administer, advise, monitor, analyze or generate information related to Clinical Research, Safety Services, Risk Evaluation and Mitigation, Patient Support Services, Evidence Development and Data Analysis; non-downloadable software as a service (SAAS) technology platforms for database management, analytics, modeling, monitoring, storage, validation, compliance, payment management, scheduling, progress monitoring, benefits verification, reimbursements and cost management related to Clinical Research, Safety Services, Risk Evaluation and Mitigation, Patient Support Services, Evidence Development and Data Analysis; providing on-line non-downloadable software, platforms, and mobile applications featuring digital assets and artificial intelligence for database management, analytics, modeling, monitoring, storage, validation, compliance, payment management, scheduling, progress monitoring, benefits verification, reimbursements and cost management in the field of clinical research, safety services, risk evaluation and mitigation, patient support services, evidence development and data analysis; scientific research consulting services in the field of pharmacovigilance strategies to ensure regulatory compliance and patient safety in clinical trials and marketed pharmaceuticals involving human subjects; scientific research consulting services in the field of epidemiology; pharmaceutical product safety testing and consultancy efficacy services for the purposes of, namely, risk mitigation and pharmacovigilance services, prescription drug monitoring programs, analyzing clinical data in healthcare databases, clinical trials, health economics and outcomes research in the fields of healthcare and pharmaceuticals, organizing, managing, and tracking data during development of a clinical trial, creating and updating clinical guidelines in the fields of healthcare and pharmaceuticals | ACTIVE | — |
| 044 | healthcare services in the nature of remote and in-person patient support services, namely, nursing services, dose administration in the nature of patient engagement to ensure adherence to dosing protocols, and patient medical diagnostic monitoring services | ACTIVE | — |
| 045 | consultation services in the field of research compliance, namely, regulatory compliance consultation services in the field of clinical trials involving human subjects; regulatory compliance consultation services in the field of informed consent protocols for clinical trial participants, Pregnancy registries, Pregnancy Root cause analysis, Risk Evaluation and Mitigation Strategy administration, Observational Research Real world Evidence, Real world Data, Knowledge Attitude and Behavior Surveys, Proprietary Risk Evaluation and Mitigation Strategy Platform, Expanded Patient Access Programs, Clinical Trial and Post Marketing Case Processing, Post Marketing Commitments, Post Marketing Requirements, Risk Minimization Plans, Risk Evaluation and Mitigation, Patient HUB, Benefit Investigation, Interventional Clinical Trials, Natural History Studies, Pragmatic Studies Design and Administration of Outcomes Based Agreements and value based agreements, Federated Registries, Integrated Registries, Decentralized Studies, and Patient Recruitment Strategies | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by United BioSource LLC
- Other trademarks owned by United BioSource LLC
- Other trademarks in Class 009
- Other trademarks in Class 016
- Other trademarks in Class 035
- Other trademarks in Class 036
- Other trademarks in Class 038
- Other trademarks in Class 041
- Other trademarks in Class 042
- Other trademarks in Class 044
- Other trademarks in Class 045
- Similar marks named UBC
- Prosecution event NOAM explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 19, 2026 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Mar 24, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Mar 24, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Mar 18, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Feb 26, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Feb 26, 2026 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Feb 26, 2026 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Feb 26, 2026 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Feb 26, 2026 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Oct 7, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 7, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 7, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 7, 2025 | XELG | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | — |
| Jul 7, 2025 | XELR | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | — |
| Apr 7, 2025 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 7, 2025 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 7, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 4, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 10, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 29, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 29, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 29, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 30, 2024 | XELG | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | — |
| Sep 30, 2024 | XELR | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | — |
| Jun 29, 2024 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 29, 2024 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 29, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 26, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 23, 2024 | MDSC | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Jan 22, 2024 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Dec 1, 2023 | NWAP | NEW APPLICATION ENTERED | — |